Introduction
============

Biliary tract cancer (BTC) is characterized by significant geographic variation; it is rarely detected in Europe and North America but has a high incidence rate in some areas of Latin America and Asia.[@b1-jcm-7-2016-033] BTC comprises aggressive tumors and has extremely poor prognosis; the five-year survival rates are 30%--50% for resectable tumors and less than 5% for unresectable cases.[@b2-jcm-7-2016-033] Although surgical resection currently remains the only potentially curative treatment, most patients are already at the advanced unresectable stage of the disease at the time of diagnosis. Systemic chemotherapy based on the combination of 5-fluorouracil with cisplatin and gemcitabine can improve the quality of life; however, the impact on survival is minimal.[@b3-jcm-7-2016-033] Therefore, new therapeutic modalities, including molecular targeting therapy, need to be explored for advanced BTC patients to improve treatment outcomes.

To date, several studies have assessed the incidence of molecular abnormalities in BTC, but the results are inconsistent.[@b4-jcm-7-2016-033],[@b5-jcm-7-2016-033] For example, the incidence of mutations of *KRAS*, *BRAF*, and *PIK3CA* genes in BTC patients varies between 0% and 60%, 0% and 22%, and 0% and 12.5%, respectively. In recent data of TCGA (the cancer genome atlas and c-bioportal), the frequencies of mutation of *KRAS*, *BRAF*, *PIK3CA*, and *FBXW7* in cholangiocarcinoma are reported to be 5.7%, 2.9%, 5.7%, and 2.9%, respectively. Overexpression of EGFR and TP53 has been detected in \~10% and 6%--35%, respectively.[@b6-jcm-7-2016-033],[@b7-jcm-7-2016-033] In addition, different carcinogenic mechanisms involving molecular abnormalities have been reported among each subdivision.[@b8-jcm-7-2016-033],[@b9-jcm-7-2016-033] However, previous studies analyzing aberrations of oncogenes or tumor suppressor genes in BTC have been conducted on relatively small patient populations, probably because of low BTC prevalence in Western countries. Therefore, unlike other major solid tumors, the molecular mechanisms underlying BTC development remain poorly understood, and their clinical significance remains elusive.

In the present study, we examined the mutation and expression of several molecules that have been reportedly associated with the development of BTCs and analyzed their correlation with patients' clinical features. The main purpose of this study was to identify the molecular characteristics of BTC that could help developing novel molecular-targeted therapies for BTC.

Materials and Methods
=====================

Subjects
--------

A total of 63 BTC patients who had undergone tumor resection and had been histologically diagnosed for adenocarcinoma of the bile duct or gall bladder at the Kyorin University Hospital between January 2005 and December 2011 were enrolled in the present study. According to the anatomical location of original tumors, BTC is subdivided into gall bladder adenocarcinoma (GBC), intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and ampulla of Vater adenocarcinoma (AC). Among the BTC patients enrolled in this study, 23 (37%) patients had GBCs, 7 (11%) patients had IHCCs, 29 (46%) patients had EHCCs, and 4 (6%) patients had ACs. Patients' clinicopathological characteristics including gender, age, lymph node metastasis, tumor differentiation, location, pTNM pathological classification according to the Union for International Cancer Control,[@b10-jcm-7-2016-033] and long-term outcome by 2014 were retrieved from medical records. The patient population included 38 (60%) males and 25 (40%) females, with a median age of 71 years ([Table 1](#t1-jcm-7-2016-033){ref-type="table"}). Although BTC treatment was heterogeneous, no patient had been administered molecular-targeted drugs. This retrospective study was approved by the Ethics Committee of the Kyorin University School of Medicine. Our research complied with the principles of the Declaration of Helsinki.

Mutational analysis of *KRAS*, *BRAF*, *PIK3CA*, and *FBXW7*
------------------------------------------------------------

Paraffin-embedded tissues were sectioned to 10-μm thicknesses and mounted as three separate slides per tissue. The resulting slides were treated three times with xylene and washed with ethanol. To minimize contamination by normal DNA, areas where at least 70% of the cells exhibited disease-specific pathology were dissected under a binocular microscope and used for DNA extraction with the DNeasy Blood & Tissue Kit (QIAGEN). We obtained polymerase chain reaction products by using Veriti^®^ Thermal Cycler (Applied Biosystems), and they were then purified by QIAamp DNA FFPE Tissue Kit (QIAGEN). Regions of the *KRAS*, *BRAF*, *PIK3CA*, and *FBXW7* genes were amplified using gene-specific primers and subjected to direct DNA sequencing as previously described.[@b11-jcm-7-2016-033]--[@b13-jcm-7-2016-033] *KRAS* point mutations were screened for codons 12 and 13 within exon 2, two hot spots that cumulatively include \>95% of this gene's mutations.[@b12-jcm-7-2016-033] *BRAF* was screened for V600E mutation within exon 15, where \>95% of point mutations occur.[@b14-jcm-7-2016-033],[@b15-jcm-7-2016-033] *PIK3CA* mutations were screened within exons 9 and 20 where \>80% of point mutations occur.[@b11-jcm-7-2016-033],[@b16-jcm-7-2016-033],[@b17-jcm-7-2016-033] *FBXW7* mutations were screened within exons 8, 11, and 12, since most of the *FBXW7* mutations (eg, R465C, R465H, R505C, and Y519C) occur within these regions.[@b18-jcm-7-2016-033]

Immunohistochemistry of EGFR and TP53
-------------------------------------

The overexpression of EGFR and TP53 was examined by immunohistochemistry. Based on the HercepTest™ (Dako) criteria, EGFR signals were defined in terms of staining intensity of the cancer cell membrane: 0, between 0% and 10% stained cells; 1+, faint and/or partial staining in \>10% cells; 2+, moderate staining in \>10% cells and strong and complete staining in 10%--30% cells; 3+, strong and complete staining in \>30% cells.[@b19-jcm-7-2016-033] For the cases showing mixed intensities, predominant signal was selected as the final score. The samples with the final score of 2+ or 3+ were considered positive for EGFR overexpression ([Fig. 1A--1](#f1-jcm-7-2016-033){ref-type="fig"}). TP53 staining was classified according to previous reports[@b20-jcm-7-2016-033] as follows: (grade 1) absent; (grade 2) present in a minority of the cells (below 10%); (grade 3) present in approximately 10%--75% of the cells; or (grade 4) present in virtually all the cells ([Fig. 1B--1](#f1-jcm-7-2016-033){ref-type="fig"}). Only the tumor cells with dense nuclear staining were graded as positive. Tumors with TP53 expression in the majority of the cells (grades 3 and 4) were classified as exhibiting TP53 overexpression.

The EGFR and TP53 staining intensities were evaluated by a surgeon (MY) and a pathologist (YO) independently.

Statistical analysis
--------------------

Associations between molecular factors and clinicopathological parameters were assessed by χ^2^ test or Fisher's exact test. Overall survival (OS) after surgery was calculated using the Kaplan--Meier method; the log-rank test was performed to compare survival curves. To identify independent predictive biomarkers for survival, multivariate analyses were performed using the Cox regression model (a log-rank test) for OS. Two-tailed *P* values of \<0.05 were considered significant. All analyses were performed using the SPSS software (SPSS for Macintosh Version 21; IBM Corporation).

Results
=======

*KRAS*, *BRAF*, *PIK3CA*, and *FBXW7* mutations in BTC
------------------------------------------------------

*KRAS* mutations were identified in 9 (14%) of the 63 BTC patients: 2 of 23 GBC cases (9%) and 7 of 29 EHCCs (24%). The G12V mutation was detected in 3 BTC patients, G12D in 5 BTC patients, and G12S in 1 BTC patient ([Table 2](#t2-jcm-7-2016-033){ref-type="table"}). OS of *KRAS* mutation-bearing patients was significantly worse than that of the patients with the wild-type *KRAS* gene ([Fig. 2A](#f2-jcm-7-2016-033){ref-type="fig"}; *P* = 0.005 by log-rank test). In addition, patients with lymph node metastasis showed higher rate of *KRAS* mutation than those without metastasis, although the difference was statistically only marginal (*P* = 0.066).

No mutations were identified within the analyzed regions of the *BRAF* (exon 15), *PIK3CA* (exons 9 and 20), and *FBXW7* genes (exons 8, 11, and 12) in BTC patients.

EGFR overexpression
-------------------

EGFR expression was absent in 58 of the 63 tumors (92%). The remaining 5 (8%) samples were scored as 2+ and considered positive for EGFR overexpression; no samples showed scores of 1+ or 3+ ([Table 2](#t2-jcm-7-2016-033){ref-type="table"}). There was no statistically significant difference in clinicopathological features between the patients with and without EGFR overexpression ([Table 3a](#t3-jcm-7-2016-033){ref-type="table"} and [Fig. 2B](#f2-jcm-7-2016-033){ref-type="fig"}).

TP53 overexpression
-------------------

TP53 overexpression was found in 30 of the 63 patients (48%; [Table 2](#t2-jcm-7-2016-033){ref-type="table"}). However, there was no statistically significant difference in clinicopathological features between the patients positive and negative for TP53 overexpression ([Table 3b](#t3-jcm-7-2016-033){ref-type="table"}). Similarly, no association between TP53 overexpression and OS was detected ([Fig. 2C](#f2-jcm-7-2016-033){ref-type="fig"}).

Multivariate analysis for OS
----------------------------

Multivariate analysis of the molecular and clinicopathological parameters of BTC (listed in [Tables 1](#t1-jcm-7-2016-033){ref-type="table"} and [2](#t2-jcm-7-2016-033){ref-type="table"}) identified *KRAS* mutation (*P* = 0.004) and lymph node metastasis (*P* = 0.015) as independent factors for shorter OS ([Table 4](#t4-jcm-7-2016-033){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this is the first study to reveal the prognostic significance of molecular abnormalities in BTC. In the present study, *KRAS* mutations were detected in 14% of BTC patients, which is within the 0%--60% range reported by other studies including TCGA.[@b4-jcm-7-2016-033],[@b5-jcm-7-2016-033],[@b21-jcm-7-2016-033],[@b22-jcm-7-2016-033] Most strikingly, the treatment outcome of *KRAS* mutation-positive patients was significantly worse than that of *KRAS* wild-type patients. To date, no studies have demonstrated the prognostic impact of *KRAS* genetic alterations in BTC, although *KRAS* has been reported as one of the most frequently mutated genes in this type of cancer. Our present data suggest that mutations in the *KRAS* gene can be used as a prognostic biomarker for BTC patients. In addition, *KRAS* may be associated with the efficacy of molecular-based therapeutic approaches to treat BTC. Currently, no approved KRAS-targeting molecular drugs have been established. However, *KRAS* mutational status is crucial for the application of anti-EGFR antibody drugs, because *KRAS* mutations usually confer resistance to these drugs in colon or lung cancers.[@b23-jcm-7-2016-033],[@b24-jcm-7-2016-033] In BTC, relationship between KRAS status and efficacy of anti-EGFR antibody drugs remains uncertain. Future studies are required to investigate the efficacy of anti-EGFR antibody-based therapy for BTC patients with *KRAS* mutations.

*BRAF* belongs to the mitogen-activated protein kinase signaling pathways, which mediate cellular response to growth factors, including EGF. *BRAF* mutations have been reported as a relatively common event (22%) in IHCC but not in EHCC, in the Anglo-Saxon population;[@b25-jcm-7-2016-033] on the other hand, they were not observed in Chinese patients with IHCC.[@b26-jcm-7-2016-033] Our present findings are consistent with the latter report, suggesting ethnic variations in the frequency of *BRAF* mutations in BTC. These results suggest that BRAF inhibitors that are effective only in the patients with *BRAF* mutation, such as vemurafenib, may not be effective in Asian patients with BTC.

*PIK3CA* encodes the catalytic subunit of PI3K that activates a downstream Akt kinase upon stimulation with various growth factors. The response rate to PI3K/Akt/mTOR pathway inhibitors has been found to be significantly higher in patients with *PIK3CA* mutations than in those with the wild-type gene.[@b16-jcm-7-2016-033],[@b27-jcm-7-2016-033] In addition, *PIK3CA* mutations in colorectal cancer have been associated with clinical resistance to anti-EGFR monoclonal antibodies.[@b28-jcm-7-2016-033],[@b29-jcm-7-2016-033] Our present study did not identify mutations in *PIK3CA* in Japanese patients with BTC, suggesting that the efficacy of PIK3CA inhibitors may be minimal in this ethnic group. However, anti-EGFR antibody-based therapy may be effective in the Japanese BTC population, provided that *PIK3CA* in BTC plays a similar role as in colorectal cancer.

Consistent with the previous report, EGFR overexpression was not detected in most BTC tumors (92%).[@b30-jcm-7-2016-033] Unlike tyrosine kinase inhibitors, cetuximab is effective in colorectal cancer patients with EGFR-negative tumors.[@b31-jcm-7-2016-033] If such is the case in BTC, cetuximab therapy may be applicable for BTC even if most cases are negative for EGFR expression. Future studies treating BTC patients with low EGFR expression by cetuximab will be necessary to address this issue.

TP53 is one of the major tumor suppressor genes involved in cell cycle, DNA repair, and apoptosis. In contrast to the previous reports, we found that the incidence of TP53 overexpression was similar between GBC and other BTC categories. In addition, no clinicopathological features were associated with TP53 overexpression. Our results suggest that TP53 overexpression may have little clinical relevance in Japanese patients with BTC.

FBXW7 is a member of the F-box family of proteins, which function as substrate recognition components of the multisubunit ubiquitin ligase SCF.[@b16-jcm-7-2016-033] FBXW7-inactivating mutations have been detected in diverse human cancers with an overall frequency of approximately 6%;[@b16-jcm-7-2016-033] the highest mutation incidence has been reported for cholangiocarcinomas in Sweden (35%).[@b16-jcm-7-2016-033] However, we did not detect *FBXW7* mutations in Japanese BTC patients. The reason for this discrepancy remains unknown; however, differences in ethnicities and the prevalence of histological subtypes could be involved. In our study, IHCC represented only 11% of all BTCs, which is consistent with previous reports of BTC histological classification in Japan.[@b32-jcm-7-2016-033] In contrast, IHCC is the dominant BTC category in Western countries.[@b33-jcm-7-2016-033] IHCC may harbor *FBXW7* mutations more frequently than other BTC subtypes. Of note, recent TCGA data show that the mutation rate of FBXW7 in cholangiocarcinoma is relatively low (2.9%), which is consistent with our result. Future studies recruiting a larger number of patients with diverse ethnic background are necessary to elucidate this issue.

This study had some limitations. It was performed retrospectively in a relatively small, heterogeneously treated population; insufficient sample size may contribute to the lack of statistical significance in some analyses. The discrepancy observed between the results of univariate and multivariate analyses may have been caused by these factors. Our findings, therefore, should be validated in subsequent prospective studies on a large number of patients before application in clinical practice.

Conclusions
===========

The present study identified *KRAS* mutations as a poor prognostic marker for BTC patients. These findings warrant future prospective studies for elucidating the efficacy of molecular-targeting drugs and its association with predictive biomarkers in BTC.
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###### 

Characteristics of patients with BTC.

  PATIENTS (n = 63)                  N (%)
  ---------------------------------- ---------
  Age (yr)                           
   Range                             45--88
   Median                            71
  Male                               38 (60)
  Female                             25 (40)
  Diagnosis                          
   Gallbladder adenocarcinoma        23 (37)
   Intrahepatic cholangiocarcinoma   7 (11)
   Extrahepatic cholangiocarcinoma   29 (46)
   Ampulla of Vater adenocarcinoma   4 (6)
  Chemotherapy after surgery         26 (41)
  No chemotherapy                    37 (59)

**Abbreviation:** BTC, biliary tract cancer.

###### 

Molecular features of patients with BTC.

  PATIENTS (n = 63)   N (%)
  ------------------- ---------
  EGFR (IHC)          
   Score 0            58 (92)
   Score 1+           0
   Score 2+           5 (8)
   Score 3+           0
  TP53 (IHC)          
    (−)               33 (52)
    (+)               30 (48)
  *KRAS* mutant       9 (14)
   G12V               3 (5)
   G12D               5 (8)
   G12S               1 (1)
  *BRAF* mutant       0
  *PIK3CA* mutant     0
  *FBXW7* mutant      0

**Abbreviations:** BTC, biliary tract cancer; IHC, immunohistochemistry.

###### 

Relationship between molecular and clinicopathological features in biliary tract cancer.

                               IHC (−)         IHC (+) (%)      *P*
  ---------------------------- --------------- ---------------- ---------
  Age                                                           
   65\<                        15              0                0.326
   65≧                         43              5 (10)           
  Gender                                                        
   Male                        35              3 (8)            1.000
   Female                      23              2 (8)            
  GBC                          21              2 (9)            0.851
  IHCC                         6               1 (14)           
  EHCC                         27              2 (7)            
  AC                           4               0                
  Stage                                                         
   0                           1               1 (50)           0.180
   I                           8               1 (11)           
   II                          34              3 (8)            
   III                         11              0                
   IV                          4               0                
  Lymphnode metastasis                                          
   (−)                         30              4 (12)           0.363
   (+)                         28              1 (3)            
  **B) TP53 OVEREXPRESSION**                                    
  Age                                                           
   65\<                        5               10 (67)          0.254
   65≧                         24              23 (49)          
  Gender                                                        
   Male                        19              18 (49)          0.443
   Female                      10              15 (60)          
  GBC                          10              13 (57)          0.548
  IHCC                         2               4 (67)           
  EHCC                         16              13 (45)          
  AC                           1               3 (75)           
  Stage                                                         
   0                           2               0                0.208
   I                           3               6 (67)           
   II                          19              18 (49)          
   III                         5               6 (55)           
   IV                          0               3 (100)          
  Lymphnode metastasis                                          
    (−)                        17              17 (50)          0.617
    (+)                        12              16 (57)          
                               **WILD TYPE**   **MUTANT (%)**   ***P***
  **C) KRAS MUTATION**                                          
  Age                                                           
   65\<                        11              2 (15)           1.000
   65≧                         39              7 (15)           
  Gender                                                        
   Male                        29              7 (19)           0.460
   Female                      21              2 (9)            
  GBC                          20              2 (9)            0.229
  IHCC                         6               0                
  EHCC                         21              7 (25)           
  AC                           3               0                
  Stage                                                         
   0                           2               0                0.557
   I                           6               2 (25)           
   II                          30              5 (14)           
   III                         9               2 (18)           
   IV                          3               0                
  Lymphnode metastasis                                          
   (−)                         30              2 (6)            0.066
   (+)                         20              7 (26)           

**Abbreviations:** IHC, immunohistochemistry; GBC, gallbladder adenocarcinoma; IHCC, intrahepatic cholangiocarcinoma; EHCC, extrahepatic cholangiocarcinoma; AC, ampulla of Vater adenocarcinoma.

###### 

Multivariate analysis of biomarkers predicting OS.

  VARIABLES                 HAZARD RATIO   *P*     95% CI
  ------------------------- -------------- ------- ---------------
  KRAS (wild-type/mutant)   8.013          0.004   1.928--33.299
  Lymphnode metastasis      4.657          0.015   1.343--16.144

**Abbreviation:** OS, overall survival.
